Femoston-conti

If you are looking for information on other Femston products, please see below:

First of all, thank you for choosing Numan. If your prescription request for Femoston-conti 0.5mg/2.5mg or 1mg/5mg Tablets has been accepted, or if you considering whether this treatment may be suitable for you, we'd like to help you learn how to use it to its best effect, and give you some important information before you start taking it. You can also refer to this page throughout your treatment.

Femoston-conti is a sequential combined a continuous combined hormone replacement therapy (HRT) that comes in two different tablet strengths (0.5mg/2.5mg and 1mg/5mg). Each tablet contains both estradiol (an oestrogen) and dydrogesterone (a progestogen).

Femoston-conti is used to relieve symptoms in postmenopausal women who are at least 12 months past their last natural period, such as hot flushes, night sweats, mood swings, and vaginal dryness. It is also licensed for the prevention of osteoporosis after menopause in women who are at a high risk of future fractures, and for whom other preventative treatments are not suitable.

Many women notice an improvement in their symptoms within a few weeks of starting treatment. However, it can sometimes take up to three months for your body to adjust and for you to feel the full benefits.

For menopausal symptoms in women with a uterus: You should take one tablet orally each day without a break between packs, at about the same time each day. Patients changing from another continuous combined preparation may start therapy at any time, but if you are changing from a continuous sequential or cyclical preparation, you should complete the 28 day cycle and then change to Femoston-conti tablets.

Missed dose: If a dose has been forgotten, you should be taken as soon as possible. If more than 12 hours have taken place since the dose should have been taken, however, you should continue with the next tablet without taking the forgotten tablet. Do not take two tablets to make up for a missed dose. The likelihood of breakthrough bleeding or spotting may be increased with missed doses. Always take this medicine exactly as instructed, and check with your healthcare provider if you are not sure.

Treatment with the lower-dose Femoston-conti preparation is a common starting dose, though your dose may be increased by your clinician prescriber depending on your symptoms and response to treatment. The goal of HRT is always to use the lowest effective dose for the shortest duration necessary to manage your symptoms.

There are no special dosage requirements for elderly patients, though experience in treating women over 65 years is limited. This medicine is not for use in children.

Pregnancy: Femoston-conti is not a contraceptive and is intended for use only in post-menopausal women. If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to your healthcare provider for advice on this. If you become pregnant while taking it, you must stop treatment immediately and contact your healthcare provider.

Breastfeeding: Femoston-conti is not indicated during breastfeeding.

This is a "bleed-free" form of HRT, but irregular bleeding or spotting is common in the first 3-6 months. If this continues beyond six months, you should see your clinician to discuss.

Common side effects of treatment with Femoston-conti tablets include headache, abdominal pain, breast tenderness and vaginal thrush. As an oral (systemic) form of HRT, Femoston-conti is associated with a small increased risk of blood clots (venous thromboembolism), stroke, and breast cancer. The risk of ovarian cancer may also be slightly increased. These risks are generally small and depend on factors like your age, medical history, and how long you take HRT for. For a full list of side effects, please see the Patient Information Leaflet provided with your medication and also linked at the bottom of this page.

Your clinician will review your treatment after three months to check how you’re responding. After that, you should have a check-up at least once a year. These reviews will assess whether HRT is still right for you, make sure your symptoms are under control, ask about any side effects and vaginal bleeding, request a check of your weight and your blood pressure, and decide if you need further tests such as a bone density scan. You should also examine your breasts regularly, and make sure to attend all routine screening appointments such as mammograms and cervical screening, if applicable to you. If you have a premature menopause, the risks of using HRT may be different, which you should discuss with your clinician.

You should stop using Femoston-conti immediately and consult your doctor if you experience any of the following: signs of a blood clot (e.g. painful swelling in the leg), a swollen face, tongue and/or throat and/or difficulty swallowing or hives, together with difficulty breathing which are suggestive of an angioedema, jaundice (yellowing of the skin or eyes), a significant increase in your blood pressure, the new onset of a migraine-type headache, or if you become pregnant. When you and your clinician decide it is time to stop HRT, the dose is often reduced gradually to help prevent your menopausal symptoms from returning suddenly.

Meningioma: The occurrence of meningiomas (single and multiple) has been reported in association with use of Femoston-conti. Patients should be monitored for signs and symptoms of meningiomas in accordance with clinical practice. If a patient is diagnosed with meningioma, any oestradiol/dydrogesterone containing treatment must be stopped. Tumour shrinkage has been observed after treatment discontinuation.

If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, you should be closely supervised, as these conditions may recur or be aggravated during treatment with Femoston-conti 0.5mg/2.5mg and 1mg/5mg Tablets, in particular:

This medicinal product does not require any special storage conditions. Keep out of reach of children.

Further information:

If you have questions about your medication, wish to discuss alternative treatment plans, or need reassurance, our clinicians are available to provide expert advice and support. Just email us at [email protected].

Lastly, please read the Patient Information Leaflet linked below and included with your treatment for a full list of side effects, contraindications, and precautions.